Skip to main content
. 2021 Dec 18;16(5):1072–1090. doi: 10.1002/1878-0261.13151

Fig. 4.

Fig. 4

MEK and SRC inhibitors synergistically inhibit proliferation. (A) AZD0424 synergistically inhibits cell viability of DLD1 and HCT116 cells in combination with trametinib or AZD6244. Mean cell viability is shown ± SEM (n = 3 independent experiments). (B) Synergy analysis for trametinib or AZD6244 in combination with AZD0424. Synergy was calculated using the ZIP synergy model. (C) Combination of AZD0424 and trametinib inhibits HCT116 (left) but not DLD1 (right) tumour growth. Tumour volumes are plotted as means ± SEM [n = 4 (DLD1) or 5 (HCT116) mice per group (2 tumours per mouse)]. *P < 0.05 (one‐way ANOVA). (D) Immunohistochemical analysis of phosphorylated SRC Tyr419 and ERK1/2 from 5‐day drug treated tumours [n = 2 mice per group (2 tumours per mouse)]. Scale bars are 100 μm for SRC Tyr419 and 250 μm for pERK1/2, respectively.